Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

FET-PET for Diagnosis and Monitoring in Patients With Low Grade Glioma

The recruitment status of this study is unknown because the information has not been verified recently.
Verified August 2012 by Ludwig-Maximilians - University of Munich.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Deutsche Krebshilfe e.V., Bonn (Germany)
Information provided by (Responsible Party):
Bogdana Suchorska, Ludwig-Maximilians - University of Munich
ClinicalTrials.gov Identifier:
NCT01089244
First received: March 17, 2010
Last updated: August 5, 2012
Last verified: August 2012
  Purpose

The aim of the study is to compare the two imaging modalities perfusion weighted MR-imaging and FET-PET in their ability to provide an accurate histological evaluation of low grade glioma and to reveal focal abnormalities within a homogeneously appearing tumor. Additionally, therapeutic effects should be assessed during a time period of two years.


Condition
Astrocytoma
Oligoastrocytoma
Oligodendroglioma

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Molecular Correlates and Clinical Significance of Positron Emission Tomography With FET-PET in Combination With Perfusion-weighted Magnetic Resonance Imaging (PWI) in Patients With Low Grade Gliomas

Resource links provided by NLM:


Further study details as provided by Ludwig-Maximilians - University of Munich:

Primary Outcome Measures:
  • Overall survival [ Time Frame: 24 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Progression Free survival [ Time Frame: 24 months ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples With DNA

High molecular wight DNA and RNA speciments for MGMT promoter methylation, IDH1/IDH2 and p53 mutation, LOH 1p and 19q analysis


Estimated Enrollment: 60
Study Start Date: June 2008
Estimated Study Completion Date: April 2013
Estimated Primary Completion Date: December 2012 (Final data collection date for primary outcome measure)
Groups/Cohorts
Group A

Patients with a suspected WHO II low grade glioma, disease progression within

1 year

Group B
Patients with a suspected WHO II low grade glioma, progression free within 1 year

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Patients with a suspected referred to a Neurosurgical Department in order to provide a diagnosis and therapy

Criteria

Inclusion Criteria:

  • neuroradiologically suspected low grade glioma (Astrocytoma WHOI-II, Oligodendroglioma WHO II, Oligoastrocytoma WHO II)
  • histological verification will be obtained either by microsurgery or by stereotactic biopsy
  • patients older than 18 years
  • Karnofsky Performance Score >=70
  • pregnant or nursing female patients will not be included in this study

Exclusion Criteria:

  • patients in whom informed consent cannot be obtained due to organic brain syndrome or insufficient language skills
  • patients who cannot lie quiet for a time period of app. two hours during the FET-PEt scan
  • medical history of a metastatic brain disease
  • patients in whom an MRI scan cannot be performed due to claustrophobia metallic protheses or pacemakers etc.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01089244

Locations
Germany
University Hospital Munich, Department of Neurosurgery
Munich, Bavaria, Germany, 81377
University Hospital, Duesseldorf
Duesseldorf, North Rhine-Westphalia, Germany, 40225
Sponsors and Collaborators
Ludwig-Maximilians - University of Munich
Deutsche Krebshilfe e.V., Bonn (Germany)
Investigators
Principal Investigator: Joerg C. Tonn, Prof. Dr. Department of Neurosurgery, LMU Munich
  More Information

No publications provided

Responsible Party: Bogdana Suchorska, PI, Ludwig-Maximilians - University of Munich
ClinicalTrials.gov Identifier: NCT01089244     History of Changes
Other Study ID Numbers: GGN-CP4
Study First Received: March 17, 2010
Last Updated: August 5, 2012
Health Authority: Germany: Federal Office for Radiation Protection

Keywords provided by Ludwig-Maximilians - University of Munich:
Low grade glioma
Astrocytoma
Molecular imaging
FET PET
Therapy monitoring
Temodar

Additional relevant MeSH terms:
Astrocytoma
Oligodendroglioma
Glioma
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Neuroectodermal Tumors

ClinicalTrials.gov processed this record on November 27, 2014